Prevalence of high-risk human papillomavirus types and cervical squamous intraepithelial lesions in women over 30 years of age in St. Petersburg, Russia

Cancer Epidemiology

Volumn 35, Issue 2, 2011, Pages 160-164

  Shipitsyna, Elena ^a   Zolotoverkhaya, Ekaterina ^a   Kuevda, Dmitry ^b   Nasonova, Veronika ^b   Romanyuk, Tatyana ^b   Khachaturyan, Armine ^a   Orlova, Olga ^a   Abashova, Elena ^a   Kostyuchek, Irina ^a   Shipulina, Olga ^b   Anttila, Ahti ^c   Savicheva, Alevtina ^a  

^a D O OTT RESEARCH INSTITUTE OF OBSTETRICS   (Russian Federation)

^b CENTRAL RESEARCH INSTITUTE OF EPIDEMIOLOGY   (Russian Federation)

^c FINNISH CANCER REGISTRY   (Finland)

Author keywords

Cervical lesion; High risk human papillomavirus; Prevalence; Russia; Screening

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RISK; COLPOSCOPY; CYTODIAGNOSIS; DNA SEQUENCE; FEMALE; GENOTYPE; GYNECOLOGIC CARE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; RUSSIAN FEDERATION; SQUAMOUS CELL; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; WART VIRUS;

ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RISK FACTORS; RUSSIA; UTERINE CERVICAL NEOPLASMS;

EID: 79953124496     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2010.08.010     Document Type: Article

References (28)

1. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., Shah K.V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002, 55:244-265.
2. World Health Organization. Human papillomavirus infection and cervical cancer; 2009. Available at http://www.who.int/vaccine_research/diseases/hpv/en/.
3. Arbyn M., Autier P., Ferlay J. Burden of cervical cancer in the 27 member states of the European Union: estimates for 2004. Ann Oncol 2007, 18:1423-1425.
4. Arbyn M., Anttila A., Jordan J., Ronco G., Schenck U., Segnan N., et al. European guidelines for quality assurance in cervical cancer screening. Second edition - summary document. Ann Oncol 2010, 21:448-458.
5. Davydov M.I., Axel E.M. Cancer statistics in Russia and the Commonwealth of Independent States in 2006. Incidence rates. J N. N. Blokhin Russian Cancer Res Center RAMS 2008, 19:52-90. [in Russian].
6. Davydov M.I., Axel E.M. Cancer statistics in Russia and the Commonwealth of Independent States in 2006. Mortality rates. J N. N. Blokhin Russian Cancer Res Center RAMS 2008, 19:91-119. [in Russian].
7. Axel E.M., Gorbachyova I.A. Cancer statistics in Russia and the Commonwealth of Independent States in 2006. Incidence and mortality in Moscow and St. Petersburg. J N. N. Blokhin Russian Cancer Res Center RAMS 2008, 19:120-134. [in Russian].
8. van Muyden R.C., ter Harmsel B.W., Smedts F.M., Hermans J., Kuijpers J.C., Raikhlin N.T., et al. Detection and typing of human papillomavirus in cervical carcinomas in Russian women. Cancer 1999, 85:2011-2016.
9. Kulmala S.M., Shabalova I.P., Petrovitchev N., Syrjänen K.J., Gyllensten U.B., Syrjänen S.M. Prevalence of the most common high-risk HPV genotypes among women in three New Independent States of the former Soviet Union. J Med Virol 2007, 79:771-781.
10. Syrjänen S., Shabalova I., Petrovichev N., Kozachenko V., Zakharova T., Pajanidi J., et al. Sexual habits and human papillomavirus infection among females in three New Independent States of the former Soviet Union. Sex Transm Dis 2003, 30:680-684.
11. Lee S.H., Vigliotti V.S., Vigliotti J.S., Pappu S. Routine human papillomavirus genotyping by DNA sequencing in community hospital laboratories. Infect Agent Cancer 2007, 5:2-11.
12. Boom R., Sol C., Beld M., Weel J., Goudsmit J., Wertheim-van Dillen P. Improved silica-guanidiniumthiocyanate DNA isolation procedure based on selective binding of bovine alpha-casein to silica particles. J Clin Microbiol 1999, 37:615-619.
13. Anttila A., Ronco G., Lynge E., Fender M., Arbyn M., Baldauf J.-J., et al. Epidemiological guidelines for quality assurance in cervical cancer screening. European guidelines for quality assurance for cervical cancer screening 2008, 11-68. Office for Official Publications of the European Communities, Luxembourg. 2nd ed. M. Arbyn, A. Anttila, J. Jordan, G. Ronco, U. Schenck, N. Segnan (Eds.).
14. Arbyn M., Raifu A.O., Bray F., Weiderpass E., Anttila A. Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer 2009, 45:2640-2648.
15. European guidelines for quality assurance for cervical cancer screening 2008, 291. Office for Official Publications of the European Communities, Luxembourg. 2nd ed. M. Arbyn, A. Anttila, J. Jordan, G. Ronco, U. Schenck, N. Segnan (Eds.).
16. International Agency for Research on Cancer. IARC Handbooks of Cancer Prevention, vol.10: Cervix Cancer Screening. Lyon: IARS Press; 2005.
17. Arbyn M., Sasieni P., Meijer C.J., Clavel C., Koliopoulos G., Dillner J. Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006, 24(Suppl. 3):78-89.
18. Arbyn M., Martin-Hirsch P., Buntinx F., Van Ranst M., Paraskevaidis E., Dillner J. Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate. J Cell Mol Med 2009, 13:648-659.
19. Syrjänen S., Shabalova I.P., Petrovichev N., Kozachenko V.P., Zakharova T., Pajanidi J., et al. Human papillomavirus testing and conventional pap smear cytology as optional screening tools of women at different risks for cervical cancer in the countries of the former soviet union. J Low Genit Tract Dis 2002, 6:97-110.
20. Stoler M.H., Schiffman M. Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001, 285:1500-1505.
21. Evans M.F., Adamson C.S., Papillo J.L., St John T.L., Leiman G., Cooper K. Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes. Cancer 2006, 106:1054-1064.
22. Andersson S., Safari H., Mints M., Lewensohn-Fuchs I., Gyllensten U., Johansson B. Type distribution, viral load and integration status of high-risk human papillomaviruses in pre-stages of cervical cancer (CIN). Br J Cancer 2005, 92(12):2195-2200.
23. Bardin A., Vaccarella S., Clifford G.M., Lissowska J., Rekosz M., Bobkiewicz P., et al. Human papillomavirus infection in women with and without cervical cancer in Warsaw, Poland. Eur J Cancer 2008, 44:557-564.
24. Silins I., Wang X., Tadesse A., Jansen K.U., Schiller J.T., Avall-Lundqvist E., et al. A population-based study of cervical carcinoma and HPV infection in Latvia. Gynecol Oncol 2004, 93:484-492.
25. Tachezy R., Hamsíková E., Hájek T., Mikysková I., Smahel M., Van Ranst M., et al. Human papillomavirus genotype spectrum in Czech women: correlation of HPV DNA presence with antibodies against HPV-16, 18, and 33 virus-like particles. J Med Virol 1999, 58(4):378-386.
26. Filipi K., Tedeschini A., Paolini F., Celicu S., Morici S., Kota M., et al. Genital human papillomavirus infection and genotype prevalence among Albanian women: a cross-sectional study. J Med Virol 2010, 82:1192-1196.
27. Aydin Y., Atis A., Tutuman T., Goker N. Prevalence of human papilloma virus infection in pregnant Turkish women compared with non-pregnant women. Eur J Gynaecol Oncol 2010, 31:72-74.
28. Sellors J.W., Mahony J.B., Kaczorowski J., Lytwyn A., Bangura H., Chong S., et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group. CMAJ 2000, 163:503-508.